Free Trial

Amylyx Pharmaceuticals (AMLX) Stock Price, News & Analysis

Amylyx Pharmaceuticals logo
$9.16 +0.66 (+7.76%)
Closing price 04:00 PM Eastern
Extended Trading
$8.90 -0.26 (-2.84%)
As of 05:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Amylyx Pharmaceuticals Stock (NASDAQ:AMLX)

Key Stats

Today's Range
$8.48
$9.19
50-Day Range
$5.02
$9.30
52-Week Range
$2.05
$9.38
Volume
949,577 shs
Average Volume
1.11 million shs
Market Capitalization
$816.80 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.75
Consensus Rating
Buy

Company Overview

Amylyx Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
65th Percentile Overall Score

AMLX MarketRank™: 

Amylyx Pharmaceuticals scored higher than 65% of companies evaluated by MarketBeat, and ranked 351st out of 929 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Amylyx Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 9 buy ratings, 2 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Amylyx Pharmaceuticals has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Amylyx Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Amylyx Pharmaceuticals are expected to grow in the coming year, from ($2.20) to ($1.36) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Amylyx Pharmaceuticals is -3.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Amylyx Pharmaceuticals is -3.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Amylyx Pharmaceuticals has a P/B Ratio of 3.82. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Amylyx Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    10.82% of the float of Amylyx Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Amylyx Pharmaceuticals has a short interest ratio ("days to cover") of 5.
  • Change versus previous month

    Short interest in Amylyx Pharmaceuticals has recently decreased by 3.75%, indicating that investor sentiment is improving.
  • Dividend Yield

    Amylyx Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Amylyx Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    10.82% of the float of Amylyx Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Amylyx Pharmaceuticals has a short interest ratio ("days to cover") of 5.
  • Change versus previous month

    Short interest in Amylyx Pharmaceuticals has recently decreased by 3.75%, indicating that investor sentiment is improving.
  • News Sentiment

    Amylyx Pharmaceuticals has a news sentiment score of 0.80. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Amylyx Pharmaceuticals this week, compared to 4 articles on an average week.
  • Search Interest

    Only 5 people have searched for AMLX on MarketBeat in the last 30 days. This is a decrease of -29% compared to the previous 30 days.
  • MarketBeat Follows

    Only 2 people have added Amylyx Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Amylyx Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    12.30% of the stock of Amylyx Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    95.84% of the stock of Amylyx Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Amylyx Pharmaceuticals' insider trading history.
Receive AMLX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amylyx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

AMLX Stock News Headlines

Amylyx Pharmaceuticals (NASDAQ:AMLX) Reaches New 1-Year High - Still a Buy?
“Sell Nvidia before earnings”
Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has been chasing the AI giant, Eric says its biggest customers are now its biggest competitors — and that could spell trouble ahead. Instead, he’s urging investors to consider a little-known hardware company that’s already starting to take off. In fact, while Nvidia has slipped over the past 30 days, this “off-the-radar” stock is up 18% — and Eric believes the run is just beginning.tc pixel
See More Headlines

AMLX Stock Analysis - Frequently Asked Questions

Amylyx Pharmaceuticals' stock was trading at $3.78 at the start of the year. Since then, AMLX stock has increased by 142.3% and is now trading at $9.16.

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) released its quarterly earnings results on Thursday, August, 7th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by $0.02.
Read the conference call transcript
.

Amylyx Pharmaceuticals (AMLX) raised $190 million in an initial public offering on Friday, January 7th 2022. The company issued 10,000,000 shares at a price of $18.00-$20.00 per share.

Amylyx Pharmaceuticals' top institutional investors include Adage Capital Partners GP L.L.C. (9.87%), Perceptive Advisors LLC (8.86%), Saturn V Capital Management LP (3.66%) and 683 Capital Management LLC (2.42%). Insiders that own company stock include Morningside Venture Investment, Joshua B Cohen, Justin B Klee, Global Investors Lp Viking, George M Milne Jr, James M Frates, Patrick D Yeramian, Camille L Bedrosian, Gina Mazzariello, Bernhardt G Zeiher and Daphne Quimi.
View institutional ownership trends
.

Shares of AMLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Amylyx Pharmaceuticals investors own include Waste Connections (WCN), American Water Works (AWK), AU Optronics (AUOTY), DiamondRock Hospitality (DRH), The RMR Group (RMR), iShares Micro-Cap ETF (IWC) and Triple Flag Precious Metals (TFPM).

Company Calendar

Last Earnings
8/07/2025
Today
8/26/2025
Next Earnings (Estimated)
11/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:AMLX
CIK
1658551
Fax
N/A
Employees
200
Year Founded
N/A

Price Target and Rating

High Price Target
$17.00
Low Price Target
$8.00
Potential Upside/Downside
+38.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
13 Analysts

Profitability

EPS (Trailing Twelve Months)
($2.50)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$301.74 million
Net Margins
N/A
Pretax Margin
-345.81%
Return on Equity
-82.48%
Return on Assets
-70.15%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
8.72
Quick Ratio
8.72

Sales & Book Value

Annual Sales
$87.37 million
Price / Sales
8.68
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.40 per share
Price / Book
3.54

Miscellaneous

Outstanding Shares
89,170,000
Free Float
78,199,000
Market Cap
$757.95 million
Optionable
Optionable
Beta
-0.46

Social Links

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

This page (NASDAQ:AMLX) was last updated on 8/26/2025 by MarketBeat.com Staff
From Our Partners